SEC
ALLO icon

Seven Eight Capital’s Allogene Therapeutics ALLO Stock Holding History

Seven Eight Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,013
Closed -$281K – 400
2022
Q3 		$281K Buy
+26,013
New +$353K 0.06% 393
2021
Q3 		– Sell
-33,100
Closed -$863K – 551
2021
Q2 		$863K Buy
+33,100
New +$944K 0.12% 295

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Seven Eight Capital's ALLO Position: Q4 2022 in Review

Seven Eight Capital sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 26,013 shares — an estimated $281K sold.

Seven Eight Capital first reported a position in ALLO in Q2 2021 and held it in 2 quarters. The position peaked at $863K in Q2 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Seven Eight Capital reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Seven Eight Capital sold 26,013 Allogene Therapeutics shares in Q4 2022, an estimated $281K.
  • Seven Eight Capital first reported a position in Allogene Therapeutics in Q2 2021 and held it in 2 quarters.
  • Seven Eight Capital's Allogene Therapeutics position peaked at $863K in Q2 2021.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Seven Eight Capital's 13F filing for Q4 2022, filed 13 Feb 2023.